Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
Close
  • Menu
  • Setting

Recombinant Human IL-13

Catalog No.
PH2014
Recombinant Human IL-13
Grouped product items
Size Price Stock Qty
10ug
$376.00
In stock
100ug
$1,265.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

No Related Posts

Background

Interleukin-13 (IL-13) is a monomeric 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergy, cancer, and tissue fibrosis. It is secreted by several helper T cell subsets, NK cells, mast cells, eosinophils, basophils, and visceral smooth muscle cells [1-3]. Mature human IL-13 shares approximately 58% amino acid sequence identity with mouse and rat IL-13. Despite the low homology, it exhibits cross-species activity between human, mouse, and rat [4]. IL-13 suppresses the production of proinflammatory cytokines and other cytotoxic substances by macrophages, fibroblasts, and endothelial cells. On B cells, it promotes cellular activation, immunoglobulin class switching to IgE, and the up-regulation of CD23/Fc epsilon RII [1, 5]. IL-13 binds with low affinity to the transmembrane IL-13 R alpha 1 which then forms a signaling complex with the transmembrane IL-4 R alpha [6-8]. This high affinity receptor complex also functions as the type 2 IL-4 receptor [6, 7]. IL-13 R alpha 2 inhibits responses to both IL-13 and IL-4. It binds IL-13 with high affinity [9, 10] and prevents IL-13 from signaling through the IL-13 R alpha 1/IL-4 R alpha complex [11, 12]. It also blocks signaling through IL-4-occupied IL-13 R alpha 1/IL-4 R alpha receptor complexes [12, 13]. In addition, IL-13-bound IL-13 R alpha 2 can directly promote tumor cell invasiveness and the development of tissue fibrosis [14-16].

Reference

[1]. Saggini, A. et al. (2011) Int. J. Immunopathol. Pharmacol. 24:305.

[2]. Gallo, E. et al. (2012) Eur. J. Immunol. 42:2322.

[3]. Liang, H.E. et al. (2012) Nat. Immunol. 13:58.

[4]. Ruetten, H. and C. Thiemermann (1997) Shock 8:409.

[5]. McKenzie, A.N. et al. (1993) Proc. Natl. Acad. Sci. USA 90:3735.

[6]. Aman, M.J. et al. (1996) J. Biol. Chem. 271:29265.

[7]. Zurawski, S.M. et al. (1995) J. Biol. Chem. 270:13869.

[8]. Andrews, A.L. et al. (2002) J. Biol. Chem. 277:46073.

[9]. Chen, W. et al. (2009) J. Immunol. 183:7870.

[10]. Daines, M.O. et al. (2007) J. Allergy Clin. Immunol. 119:375.

[11]. Kasaian, M.T. et al. (2011) J. Immunol. 187:561.

[12]. Andrews, A.-L. et al. (2006) J. Allergy Clin. Immunol. 118:858.

[13]. Rahaman, S.O. et al. (2002) Cancer Res. 62:1103.

[14]. Fujisawa, T. et al. (2009) Cancer Res. 69:8678.

[15]. Fujisawa, T. et al. (2011) Int. J. Cancer 131:344.

[16]. Fichtner-Feigl, S. et al. (2006) Nat. Med. 12:99.

Description

Accession #

AAK53823

Alternate Names

Human IL13; interleukin-13; IL13; IL-13; interleukin 13; MGC116786

Source

Human embryonic kidney cell, HEK293-derived human IL-13 protein

Protein sequence

Gly21-Asn132

M.Wt

13.3 kDa

Appearance

Solution protein.

Stability & Storage

Avoid repeated freeze-thaw cycles. It is recommended that the protein be aliquoted for optimal storage. 12 months from date of receipt, -20 to -70 °C as supplied.

Concentration

0. 2 mg/mL

Formulation

Dissolved in sterile PBS buffer.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. This solution can be diluted into other aqueous buffers.

Biological Activity

Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The EC50 for this effect is 0.5-2.0 ng/mL.

Shipping Condition

Shipping with dry ice.

Handling

Centrifuge the vial prior to opening.

Usage

For Research Use Only! Not to be used in humans.

Quality Control

Quality Control & DataSheet

View current batch:
    Purity > 95%, determined by SDS-PAGE.
    Endotoxin: <0.010 EU per 1 ug of the protein by the LAL method.
  • Datasheet